These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37137851)

  • 21. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
    Wen QP; Qian H; Ba S; Lu MJ; Silang LDJ; Shi L
    Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):304-308. PubMed ID: 35462487
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis].
    Wu G; He H; Li H; Chen W
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):604-8. PubMed ID: 25243962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.
    Keating GM
    Drugs; 2011 Dec; 71(18):2511-29. PubMed ID: 22141390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis.
    Wang N; Hu HD; Sun H; Feng Q; Hu P; Liu Q; Ren H
    Turk J Gastroenterol; 2013; 24(3):230-40. PubMed ID: 24226716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical efficacy of entecavir combined with Biejiajian pills and its influence on TCM syndrome scores during the treatment of chronic hepatitis B with hepatic fibrosis and blood stasis syndrome].
    Cheng DY; Guo P; Sun FX; Wang XJ; Li W; Chen Q; Zhou GQ; Wang RB; Xing HC
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):608-613. PubMed ID: 37400385
    [No Abstract]   [Full Text] [Related]  

  • 29. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
    Zuo SR; Zuo XC; Wang CJ; Ma YT; Zhang HY; Li ZJ; Song LY; Deng ZZ; Liu SK
    J Clin Pharmacol; 2015 Mar; 55(3):288-97. PubMed ID: 25293471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.
    Xu Y; Zhang YG; Wang X; Qi WQ; Qin SY; Liu ZH; Jiao J; Wang JB
    World J Gastroenterol; 2015 Jul; 21(25):7869-76. PubMed ID: 26167087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
    Zhang J; Ying H; Wei L; Hong LJ
    Eur Rev Med Pharmacol Sci; 2017 Jan; 21(2):416-420. PubMed ID: 28165543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of glycyrrhizic acid preparations aimed at improving liver function of patients with chronic hepatitis B: A network meta-analysis of 53 randomized controlled trials.
    Gao W; Zhao Y; Guo L; Wang Y; Gong H; Zhang B; Yan M
    Phytomedicine; 2023 Jul; 116():154883. PubMed ID: 37224775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis.
    Wang T; Zhou X; Liu H; Wang J; Zhang P; Zhu Y; Li K; Wei S; Li H; Wang L; Wang R; Zhao Y
    Phytother Res; 2018 May; 32(5):757-768. PubMed ID: 29235181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
    Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review.
    Liang J; Tang YF; Wu FS; Deng X
    Pharmazie; 2012 Nov; 67(11):883-90. PubMed ID: 23210236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
    Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Dahuang zhechong formula on liver fibrosis in patients with chronic hepatitis B: a meta-analysis.
    Wei F; Lang Y; Gong D; Fan Y
    Complement Ther Med; 2015 Feb; 23(1):129-38. PubMed ID: 25637160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
    Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
    World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
    Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
    Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.